CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Oxymorphone Extended Releasedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00225797
NCT00225797Phase 3Completed
CompareCT.gov

An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Naïve Patients With Chronic Low Back Pain

Endo Pharmaceuticals·interventional·Posted Sep 26, 2005·Updated Jan 2, 2024

In Brief

A Phase 3 clinical trial evaluating Oxymorphone Extended Release for Chronic Pain. Completed, across 33 sites.

Detailed Summary

The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in non-cancer patients with chronic low back pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 26, 2005
Enrollment StartNov 1, 2004
Study CompletionJul 1, 2005
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

Oxymorphone Extended Releasedrug